During Tuesday’s Senate hearing on drug pricing, each of the seven pharma execs insisted their companies have never withheld samples from generic rivals, a step that has raised concerns about unfairly thwarting competition. This is because generic companies need samples to develop copycat medicines and, sometimes, run tests to show a product is bioequivalent in order to win regulatory approval.

Yet a recent Food and Drug Administration list of drug makers that withheld samples includes two companies  — Pfizer (PFE) and AstraZeneca (AZN) — whose chief executives testified samples were, in fact, not withheld.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Their lips were moving! It woud be really satisfying to see them Waterboarded, which could be the only way to get to the truth.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy